Navigation Links
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Date:6/26/2008

INDIANAPOLIS, June 27 /PRNewswire-FirstCall/ -- Eli Lilly and Co (NYSE: LLY) and Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion supporting the approval of Cymbalta(R) (duloxetine hydrochloride) for the treatment of Generalised Anxiety Disorder (GAD).

The positive opinion is based upon the results of five clinical studies -- four double-blind placebo-controlled studies and a relapse prevention study -- involving more than 2,000 non-depressed adults with GAD. In each of the four placebo-controlled studies safety and efficacy were assessed. Duloxetine significantly improved core anxiety symptoms (as measured by the Hamilton Anxiety Scale), compared with placebo (p less than or equal to 0.001, p=0.02, p=0.007, p less than or equal to 0.001 respectively) (1,2,3,4) and demonstrated improvement in role functioning, including ability to perform everyday activities in work, home and in social situations.(5,6) In addition, duloxetine significantly decreased the likelihood of relapse in those patients who initially responded to duloxetine and were maintained on treatment for six months compared with those switched to placebo.(7) The most common side effects in these studies included nausea, fatigue, dry mouth, drowsiness, constipation, insomnia, decreased appetite, hyperhidrosis, decreased libido, vomiting, ejaculation delay and erectile dysfunction.

Although global prevalence is not currently known, more than nine million Europeans (8,9) and six million people in Central and South America are estimated to suffer from GAD.(10) Difficult to detect, due to the fact that the condition presents with a variety of symptoms,(11) GAD is characterised by more than simple anxiety. The disorder is diagnosed when patients suffer from excessive anxiety and worry about a number of events and activities (such as performance at work or school) over a
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
2. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association
3. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
4. XTENT Announces European Regulatory Update
5. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
6. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
7. European Unions CHMP Issues Positive Opinion on Sugammadex
8. PLC Systems Announces Approval of First European Study to Evaluate RenalGuard(TM)
9. PRoFESS(R) Results Announced at XVII European Stroke Conference
10. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
11. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
(Date:8/21/2014)... PARK, N.J. , Aug. 21, 2014 /PRNewswire/ ... pharmacy group purchasing organization (GPO), is pleased to ... to collaborate on a host of innovative specialty ... help Aurora deliver enhanced therapy management services to ... Management (OTM) system. Aurora will use ...
(Date:8/21/2014)... 21, 2014  The board of directors of VirtualScopics, ... of clinical trial imaging solutions, today announced that ... officer, effective immediately.  Mr. Groff has held the role ... joined VirtualScopics in January 2006 as an accounting manager ... "When the board of VirtualScopics asked Jim to ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... BILLERICA, Mass., Sept. 15 HydroCision Inc. ( ... announced today the purchase of the majority of ... capital firms Volcano Capital, Bioventures, and Omega Funds. ... SpineJet®, whose innovative Fluidjet surgical technology allows discectomy ...
... VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the ... the treatment of cancer, respiratory and inflammatory diseases, announced ... FierceBiotech "Fierce 15" list, designating it as one of ... industry. Every year, FierceBiotech evaluates hundreds of private companies, ...
Cached Medicine Technology:HydroCision Announces New Investment to Accelerate Growth of Novel Fluidjet Technology for Minimally Invasive Spine Surgery 2FierceBiotech Names VentiRx Pharmaceuticals as One of the 'Fierce 15' Biotech Companies of 2010 2
(Date:8/21/2014)... 21, 2014 Today, Zane Benefits, the ... the premium tax credits in 2015. , According to ... part of the Affordable Care Act (ACA), premium tax ... individual health insurance through the Health Insurance Marketplaces. , ... and the amount of the tax credits, updated for ...
(Date:8/21/2014)... MI (PRWEB) August 21, 2014 An ... informing a taxpayer that their federal tax payment is ... domain appears to come from the IRS, “tax@irs.gov”, it’s ... to provide personal and financial information. , While similar ... now, an uptick in phishing activity is occurring right ...
(Date:8/21/2014)... heart-lung support technology, the University of Michigan,s Transplant Center ... and pancreases available for transplant by about 20 percent. ... Transplantation and detail the impact of more than ... to improve the quality and viability of organs donated ... limited by the number of donated organs available, so ...
(Date:8/21/2014)... to exercise is a challenge. Thankfully, there are Zombies chasing ... of more than 31,000 health and fitness apps on the ... that use games to increase physical activity. , Gamification is ... to cash in to help people get fit. Whether or ... seen. , "It,s just been assumed that gamified apps will ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pulmonary ... with an Education Forum for PH patients and ... Who:    The Pulmonary Hypertension Association – the ... find ways to prevent and cure pulmonary hypertension ... affects the functioning of the heart and can ...
Breaking Medicine News(10 mins):Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2Health News:Playing hunger games: Are gamified health apps putting odds in your favor? 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3
... , BETHEL, Conn., Dec. 4 MedClean Technologies, Inc. ... a preferred stock purchase agreement with Socius Capital Group, LLC, a ... Capital Group, LLC. Pursuant to the Purchase Agreement, MedClean will receive ... to sell up to 750 shares of its Series C Preferred ...
... , UNION, N.J., Dec. 4 ... its specialty anatomic pathology services with the launch of ... company,s expansion from a regional laboratory to a leading ... full range of specialties including gastroenterology, urology and now ...
... , , OKLAHOMA CITY, Dec. 4 ... for the first quarter ended September 30, 2009, a 24% decrease ... income for the quarter were $133,681 and $80,402, respectively, each a ... impacted by a decrease in pharmacy sector sales. This trend ...
... , SEATTLE, Dec. 4 The National Cancer Institute ... Research Center to become the nation,s sole operator of its Cancer ... jobs at the Hutchinson Center - nearly tripling the size of ... operational, which is scheduled for March 15, 2010. The Seattle CIS ...
... Medicine (BUSM) researchers at the Slone Epidemiology Center found that ... reduced incidence of uterine leiomyomata (fibroids). This report, based on ... of the American Journal of Epidemiology . Uterine ... to three times more common among black women than white ...
... ... initiative to establish standards for language access in healthcare organizations. , ... Hudson, OH (PRWEB) ... solutions, and patient education materials for healthcare institutions, understands the importance of effective ...
Cached Medicine News:Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 2Health News:MedClean Technologies Enters Into Preferred Stock Agreement of Up to $7.5 Million 3Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3Health News:PD-Rx Pharmaceuticals, Inc. Reports 1st Quarter Earnings 2Health News:Hutchinson Center Wins $55.4 Million Contract to Become Sole Operator of the NCI Cancer Information Service 2Health News:Researchers find increased dairy intake reduces risk of uterine fibroids in black women 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 2Health News:Lexi-Comp Focused on Improving Patient Communication in Healthcare Institutions Treating Diverse Patient Populations 3
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Microforceps : Eckardt End & Side Gripping Forceps...
Medicine Products: